<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LAMOTRIGINE</span><br/>(la-mo'tri-geen)<br/><span class="topboxtradename">Lamictal<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span><br/><b>Prototype: </b>Phenytoin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg, 150 mg, 200 mg tablets; 2 mg, 5 mg, 25 mg chewable tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Anticonvulsant. The exact mechanism of action is not known; thought to act by inhibiting the release of glutamate, an excitatory
         neurotransmitter, at voltage-sensitive sodium channels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Stabilizes neuronal membranes and inhibits neurotransmitter release (i.e., glutamate) in brain tissue.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial seizures in adults and children (&gt;2 y). Generalized tonicclonic, absence, or myoclonic
         seizures in adults, treatment of bipolar disorder.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to lamotrigine, lactation. Safety and efficacy in children <img src="../images/special/lesserorequal.gif"/>2
         y are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency, concomitant administration of other anticonvulsants, pregnancy (category C), cardiac or liver function
         impairment. Note: Fatal rash has been reported in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Partial Seizures, Patients Receiving Anticonvulsants Other Than Valproic Acid</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 50 mg q.d. for 2 wk, then 50 mg b.i.d. for 2 wk, may titrate up to 300500 mg/d in 2 divided doses (max: 700
               mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>216 y,</i> 1 mg/kg b.i.d. times 2 wk, then 2.5 mg/kg b.i.d. times 2 wk, then 5 mg/kg b.i.d. (max: 15 mg/kg/d or 400 mg/d)<br/><br/><span class="indicationtitle">Partial Seizures, Patients Receiving Valproic Acid</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 25 mg q.o.d. for 2 wk, then 25 mg q.d. for 2 wk, may titrate up to 150 mg/d in 2 divided doses (max: 200 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>216 y,</i> 0.2 mg/kg/d <small>x</small> 2 wk, then 0.5 mg/kg/d <small>x</small> 2 wk, then 1 mg/kg/d (max: 5 mg/kg/d or 250 mg/d)<br/><br/><span class="indicationtitle">Bipolar Disorder, Patients Not Receiving Valproate or Carbamazepine</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 25 mg q.d. for 2 wk, then 50 mg q.d. for 2 wk, then 100 mg/d for 1 wk, then 200 mg q.d.<br/><br/><span class="indicationtitle">Bipolar Disorder, Patients Receiving Valproic Acid</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 25 mg q.o.d. for 2 wk, then 25 mg q.d. for 2 wk, then 50 mg q.d. for 1 wk, then 100 mg q.d.<br/><br/><span class="indicationtitle">Bipolar Disorder, Patients Receiving Carbamazepine</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 50 mg q.d. for 2 wk, then 50 mg b.i.d. for 2 wk, then 100 b.i.d for 1 wk, then 150 mg b.i.d. for 1 wk, then 200
               mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: Reduced dose may be warranted with renal and hepatic impairment.
            			
         </li>
<li>Ensure that chewable tablets are chewed or crushed before being swallowed with a liquid.</li>
<li>When discontinued, drug should be tapered off gradually over a 2-wk period, unless patient safety is at risk.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, ataxia, somnolence, headache,</span> aphasia, vertigo, confusion, slurred speech, irritability, depression, incoordination, hostility. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, anorexia, abdominal pain, diarrhea, dyspepsia, constipation. <span class="typehead">Urogenital:</span> Hematuria, dysmenorrhea, vaginitis. <span class="typehead"> Special Senses:</span>
<span class="speceff-common">Diplopia, blurred vision</span>. <span class="typehead">Musculoskeletal:</span> Peripheral neuropathy, chills, tremor, arthralgia. <span class="typehead">Skin:</span> Rash (including <span class="speceff-life">Stevens-Johnson syndrome, toxic epidermal necrolysis</span>), urticaria, pruritus, alopecia, acne. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Rhinitis,</span> pharyngitis, cough. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Carbamazepine,</b>
<b>phenobarbital,</b>
<b>primidone,</b>
<b>phenytoin,</b>
<b>fosphenytoin,</b>
<span class="classification">oral contraceptives</span> may decrease lamotrigine levels. <b>Valproic acid</b> may increase lamotrigine levels. Lamotrigine may decrease serum levels of <b>valproic acid.</b> May affect efficacy of <span class="classification">oral contraceptives.</span> Chronic <b>acetaminophen</b> use may affect serum concentrations of lamotrigine. <span class="typehead"> Herbal:</span>
<b>Ginkgo</b> may decrease anticonvulsant effectiveness. <b>Evening primrose</b> oil may affect seizure threshold. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 98% reaches systemic circulation. <span class="typehead">Onset:</span> 12 wk. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Distribution:</span> 55% protein bound; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to inactive metabolite. <span class="typehead">Elimination:</span> Can induce own metabolism; excreted in urine. <span class="typehead">Half-Life:</span> 2530 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug if rash develops and immediately report to physician.</li>
<li>Monitor the plasma levels of lamotrigine and other anticonvulsants when given concomitantly.</li>
<li>Monitor for adverse reactions when lamotrigine is used with other anticonvulsants, especially valproic acid.</li>
<li>Be aware of drug interactions and closely monitor when interacting drugs are added or discontinued.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician for any of the following: Worsening seizure control, skin rash, ataxia, blurred vision or diplopia, fever
            or flu-like symptoms.
         </li>
<li>Do not drive or engage in other potentially hazardous activities until response to the drug is known.</li>
<li>Use protection from sunlight or ultraviolet light until tolerance is known; drug increases photosensitivity.</li>
<li>Women using oral contraceptives to avoid pregnancy should add a barrier contraceptive.</li>
<li>Schedule periodic ophthalmologic exams with long-term use.</li>
<li>Do not discontinue lamotrigine abruptly.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>